Verve's results fell short of high expectations, according t...
Verve's results fell short of high expectations, according to analysts. Liver enzyme elevation observed in patients has sparked worries, despite assurances from the company's chief scientific officer.
Verve Therapeutics' Stock Falls 40% as Analysts Question Safety of Cholesterol-cutting Gene-editing Treatment
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment